Effect of Di-ethyl aminoethyl (DEAE) Dextran on the infectivity titre of sheep pox virus in-vitro and in-vivo

Olaf E. Nakhla*, Namaa A. Mohamed, Manal Awad, Mervat M. Ali

Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt.

The effect of diethyl aminoethyl (DEAE) dextran on the infectivity titre of sheep pox virus (SPV) was studied with different concentrations (25, 50, 75, 100 µg/ml) of DEAE-dextran on Vero cell culture. It was found that 25 and 50µg/ml were not toxic. The same concentrations were used with sheep pox virus inoculum showing that the best virus titre (10^{6.5} TCID_{50}/ml) reached with the use of 25µg/ml DEAE-dextran after 10 passages. The enhanced viral fluid was tested in-vivo, by vaccination of susceptible lambs and challenge of them with the virulent sheep pox virus. These lambs showed complete protection against the disease. The SP neutralizing antibody indices (NI) were estimated in the collected serum samples post vaccination and challenge; confirmed that 25µg of DEAE-dextran/ml virus-inoculum induced an increase in neutralizing antibodies in comparison with those induced by currently used sheep pox vaccine.

Pox viral diseases affect most animal species and are of considerable economic importance in many regions of the world. Sheep pox disease causes severe financial loss in the international trade in animals and animal productivity, lower quality of wool and leather with death of unweaned lambs (Oguzoglu et al., 2006).

Sheep pox disease is characterized by fever, generalized papules or nodules, vesicles, internal lesions (partially in the lungs) and death (OIE, 2004).

Vaccination with the attenuated live sheep pox virus vaccine is the only mean for controlling this disease through stimulating the immune system of the susceptible lambs to produce antibodies against sheep pox virus (SPV) (Ivan'yushchenkov et al., 1990). The enhancement of viral infectivity in cell culture systems by DEAE-dextran was well documented for a number of viruses (Sasaki et al., 1981; Soad, 1986; Zeneib, 2006; Bassiouney, 2007).

So, the present study was conducted in a trial to increase the infectivity titre of the SPV using DEAE-dextran, to obtain a maximum titre of the virus in cell culture and consequently allowing massive production of the vaccine with possibility of cost reduction.

Materials and methods

Animals. Nine susceptible Balady lambs about 4 months old not vaccinated against sheep pox disease and their sera were tested to prove that they are free from antibodies against SPV. They were used for potency and challenge test.

Sheep pox virus (SPV). SPV was kindly supplied by Pox Vaccine Research Dept., Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo (VSVRI). It has a titre of 10^{5.8} TCID_{50}/ml. It was used with different concentrations of DEAE-Dextran for vaccine preparation.

Virulent sheep pox virus. Virulent SPV (Egyptian strain) was obtained from Pox Dept., Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Abbasia, Cairo. It was used for challenge test of vaccinated lambs.

Sheep pox vaccine. Living attenuated sheep pox virus vaccine was kindly obtained from Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Pox Vaccine Research Dept. It has a titre of 10^{5.5} TCID_{50}/ml.

Cell culture. African green monkey kidney cell line (Vero) was subcultured and maintained at Pox Vaccine Research Dept., VSVRI. Vero cells were used for preparation of SP vaccine and virus neutralization test.

Diethyl aminoethyl (DEAE) dextran. It was obtained from Formerly ICN Biomedical Inc. as DEAE powder form. Different stock solutions of DEAE-dextran were prepared by dissolving 25, 50, 75 and 100 mg in 100 ml (for each concentration) of 0.25 M Tris-HCl buffer at pH 8.2. These solutions were sterilized by autoclaving and their pH was measured to be 7.6-7.8 and kept at room temperature until used according to Anderson et al., (1971).

Cytotoxic effect of DEAE-dextran on Vero cell culture. Different concentrations of DEAE-dextran (25, 50, 75, 100 µg/ml) were added to the growth media of Vero cell culture to determine the optimum concentration that can be
used without toxic effect on the cell culture according to Saber et al., (1984).

The effect of DEAE-dextran concentrations on propagation and titration of SPV. Vero cells were infected with SPV without adding DEAE-dextran and other cells were infected with SPV and DEAE-dextran at different concentrations (25 and 50 µg/ml). Virus titration was applied according to Virology A Laboratory Manual (1992).

Potency and challenge tests. Three groups of susceptible lambs were used, each of which consisted of 3 animals (groups I, II and III). Group (I) was vaccinated with the field dose of the currently used SPV vaccine (10⁵ TCID₅₀/animal), 0.5 ml injected intradermally (I/D) in the ventral aspect of the tail. Group (II) was vaccinated with the enhanced SPV vaccine with 25µg/ml DEAE-dextran after adjusted to the titer of the required field dose, and group III was kept as non-vaccinated controls. Lambs were intradermally injected four weeks post vaccination with 0.5 ml (100 virus particles) of the virulent sheep pox virus in the ventral aspect of the tail.

Serum samples. Serum samples were collected from vaccinated and unvaccinated control lambs post vaccination and challenge at weekly intervals for 6 weeks.

Virus neutralization Test (SNT). Virus neutralization test was used for detection of sheep pox virus neutralizing antibodies for all tested lambs and calculated with neutralizing indices according to Martin et al., (1975).

Results and Discussion

Live vaccines give long lasting immune response against most or all viral antigens. This immune response depends on the replication of the virus to give large antigenic dose and induce a balanced response (Whitton and Oldstone, 1996). The present work studied the enhancement of infectivity titre of live attenuated sheep pox virus using DEAE-dextran. Different concentrations of DEAE-dextran (25, 50, 75 and 100 µg/ml) were used in media maintaining Vero cell line. The obtained results showed that the cells maintained with the concentrations 25 and 50µg/ml had no harmful cytotoxic effect, while 75 and 100 µg/ml concentrations were completely toxic, so both of them were excluded which is agreed with the findings of (Zeneib, 2006).

The sheep pox virus was mixed with DEAE-dextran solution in a final concentration of 25 and 50µg/ml inoculum and inoculated on Vero cell monolayers for serial passages and the virus titre was estimated for each passage. The results recorded in (Table 1) demonstrated that the virus infectivity reached titre (10⁵.3 and 10⁶.4 TCID₅₀/ml) respectively with the previous concentrations at 10⁶ passage which is higher than the titre of the SPV without DEAE-dextran (10⁵.8 TCID₅₀/ml).

Thus, it is preferable to use the lowest concentration of DEAE-dextran (25µg/ml) that giving a non significance difference lower virus titer (10⁰.1 TCID₅₀/ml) than the concentration 50µg/ml, for economic purpose. These results indicated that DEAE-dextran as polycations enhanced the adsorption and uptake of the virus onto Vero cell line by creating a favourable ionic charge for virus attachment (Tessy et al., 2004), or by inhibiting the extracellular and the intracellular strong nuclease activity which destroy the messenger RNA coded by viral DNA (Samira, 2001; Bassiouny, 2007) which reflect on increasing the virus infectivity.

The evaluation of the selected enhanced sheep pox virus with 25 µg/ml DEAE dextran in addition to the currently used vaccine was pursued by vaccination of susceptible lambs with both vaccines. The results showed that the vaccinated lambs of both groups resisted the challenge with the virulent sheep pox virus, which means that the antibodies produced from both vaccines were sufficient to protect animals from the infection.

Virus neutralization test on serum samples collected at different time intervals post vaccination and challenge was conducted to evaluate the humoral immune response. The obtained neutralizing indices showed that the neutralizing antibodies, titre in lambs vaccinated with enhanced sheep pox virus was (2.3 NI) but it was (2.1 NI) in those vaccinated with the non-enhanced sheep pox vaccine 21 days post vaccination as recorded in (Table 2) and this increase referred to the immunostimulant effect of DEAE-dextran (Anderson et al., 1971; Soad, 1986).The study proved that DEAE-dextran enhanced sheep pox virus replication in Vero cells and the virus fluid prepared with it and injected with the field dose induce good immune response in vaccinated animals enabling them to resist the challenge. So, on the production scale, the prepared enhanced SPV titre could be adjusted to reach the same yield titre of the current prepared vaccine which can save time, labour and finance of the production of SPV vaccine.
Table (1): Effect of different concentration of DEAE-dextran on the infectivity titre of sheep pox virus on Vero cell line.

<table>
<thead>
<tr>
<th>Number of passages</th>
<th>SPV titre without DEAE-dextran (log 10 TCID&lt;sub&gt;50&lt;/sub&gt;/ml)</th>
<th>SPV titre using 25μg/ml of DEAE-dextran (log 10 TCID&lt;sub&gt;50&lt;/sub&gt;/ml)</th>
<th>SPV titre using 50μg/ml of DEAE-dextran (log 10 TCID&lt;sub&gt;50&lt;/sub&gt;/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5.8</td>
<td>5.8</td>
<td>5.7</td>
</tr>
<tr>
<td>2</td>
<td>5.7</td>
<td>5.8</td>
<td>5.8</td>
</tr>
<tr>
<td>3</td>
<td>5.6</td>
<td>5.8</td>
<td>5.9</td>
</tr>
<tr>
<td>4</td>
<td>5.8</td>
<td>5.9</td>
<td>6.0</td>
</tr>
<tr>
<td>5</td>
<td>5.9</td>
<td>6.0</td>
<td>6.1</td>
</tr>
<tr>
<td>6</td>
<td>5.8</td>
<td>6.1</td>
<td>6.1</td>
</tr>
<tr>
<td>7</td>
<td>5.8</td>
<td>6.2</td>
<td>6.2</td>
</tr>
<tr>
<td>8</td>
<td>5.5</td>
<td>6.2</td>
<td>6.3</td>
</tr>
<tr>
<td>9</td>
<td>5.7</td>
<td>6.3</td>
<td>6.4</td>
</tr>
<tr>
<td>10</td>
<td>5.8</td>
<td>6.3</td>
<td>6.4</td>
</tr>
</tbody>
</table>

Table (2): SPV neutralizing antibody index (NI).

<table>
<thead>
<tr>
<th>Weeks post vaccination</th>
<th>Group (I)</th>
<th>Group (II)</th>
<th>Group (III)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.9</td>
<td>1.1</td>
<td>0.0</td>
</tr>
<tr>
<td>2</td>
<td>1.5</td>
<td>1.8</td>
<td>0.0</td>
</tr>
<tr>
<td>3</td>
<td>2.1</td>
<td>2.3</td>
<td>0.0</td>
</tr>
<tr>
<td>4*</td>
<td>2.0</td>
<td>2.3</td>
<td>0.0</td>
</tr>
<tr>
<td>5</td>
<td>1.8</td>
<td>2.1</td>
<td>1.2</td>
</tr>
<tr>
<td>6</td>
<td>2.1</td>
<td>2.3</td>
<td>1.8</td>
</tr>
</tbody>
</table>

Group (I): Lambs vaccinated with the currently used sheep pox vaccine
Group (II): Lambs vaccinated with the prepared sheep pox vaccine enhanced with 25μg/ml DEAE-dextran
Group (III): Non-vaccinated controls lambs

* Challenge time with the virulent sheep pox virus

References